Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension（RSDARH）

Resistant Hypertension Clinical Trial

Official title:

Efficacy and Safety of Renal Sympathetic Denervation From the Adventitia on Resistant Hypertension.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03758196
• Other study ID #: HenanICE201802
• Status: Recruiting
• Phase: N/A
• Start date: October 31, 2018
• Est. completion date: December 31, 2021

Study information

• Verified date: March 2020
• Source: Henan Institute of Cardiovascular Epidemiology
• Contact: Yahui Liu, Bachelor
• Phone: +86 18317898825
• Email: 1182600873[@]qq.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

As one of the most common chronic diseases,The adult prevalence of hypertension is approximately 26.4% at present and will rise to 29.2% by 2025.Renal sympathetic denervation from the intima of renal artery has emerged as a potential treatment for resistant hypertension. However, renal sympathetic nerve are mainly located in the adventitia,and there is no report on renal sympathetic denervation from the adventitia of renal artery.This study is a multicenter,randomized,single-blind study,and aimed to observe the safety and efficacy of radiofrequency ablation of the renal artery from the adventitia on the basis of laparoscopic techniques for patients with resistant hypertension.

Description:

This study is a multicenter,randomized,single-blind study,and aimed to observe the safety and efficacy of radiofrequency ablation of the renal artery from the adventitia on the basis of laparoscopic techniques for patients with resistant hypertension.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 126
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1.18 years old = age = 65 years old; 2.Patients with clear diagnosis of resistant hypertension prior to enrollment:On the basis of improving lifestyle, a reasonable and tolerable amount of 3 or more kinds of antihypertensive drugs (including diuretics) for more than one month, clinic SBP=140mmHg or (and) DBP=90mmHg, 24 hours dynamic Blood pressure monitoring SBP>130mmHg or (and) DBP>80mmHg; 3.Estimated GFR (eGFR) = 60ml/min/1.73m2; 4.The patient or his legal guardian has signed the informed consent; 5.Patients who are willing and able to perform follow-up visits.

Exclusion Criteria:

1. Patients with secondary hypertension caused by any known cause;

2. pregnant or planning to be pregnant;

3. Patients with renal artery diameter <4mm or length <20mm;

4. Patients with renal artery abnormalities include: hemodynamic or anatomically significant stenosis (=50%) of renal arteries on either side;renal arterial balloon angioplasty or stenting;renal involvement on either side Multiple renal arteries,and renal arteries supply <75% of the kidneys;abnormal renal artery anatomy,such as tumor expansion;

5. Patients with cardiovascular instability factors includes:acute myocardial infarction within six months,unstable angina or cerebrovascular disease;heart valve disease with significantly altered hemodynamics;

6. Patients with other serious organic diseases;

7. Patients participated in other studies.

Related Conditions & MeSH terms

• Hypertension
• Resistant Hypertension

Intervention

Device:
• Radiofrequency ablation instruments
Renal Sympathetic Denervation from the adventitia of renal artery

Locations

Country	Name	City	State
China	Zhengzhou university People's Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Henan Institute of Cardiovascular Epidemiology

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in 24-hour average systolic blood pressure by ABPM in 6 months after discharge .		Baseline to 6 months
Secondary	Change in types and doses of antihypertensive medications in 1,3,6,12 months after discharge.		Baseline to 1 months,3 months,6 months,12 months
Secondary	Change in 24-hour average diastolic blood pressure,daytime and nighttime systolic/diastolic blood pressure by ABPM in 6 months after discharge		Baseline to 6 months
Secondary	Change in 24-hour average blood pressure,daytime and nighttime systolic/diastolic blood pressure by ABPM in 1,3,12 months after discharge		Baseline to 1 months,3 months,12 months
Secondary	Change in office systolic/diastolic blood pressure in 1,3,6,12 months after discharge		Baseline to 1 months,3 months,6 months,12 months
Secondary	Change in systolic/diastolic blood pressure by home blood pressure monitoring in 1,3,6,12 months after discharge		Baseline to 1 months,3 months,6 months,12 months
Secondary	renal function in 1,3,6,12 months after discharge		Baseline to 1 months,3 months,6 months,12 months
Secondary	The surgical complications of renal artery perforation,such as stenosis,and dissection associated with radiofrequency surgery.And major cardiovascular and cerebrovascular events ,including cardiac death,stroke and nonfatal- myocardial infarction.		Baseline to 6 months,12 months